MYC and medulloblastoma: In addition to the identification and further validation of established genomic events in medulloblastoma (e.g. MYC amplification, CDKN2A/B homozygous deletion [1], [2], [6]–[8]), defects have been identified which will, following further validation, aid investigations of the critical genetic targets of common medulloblastoma chromosomal aberrations.